MERIT MEDICAL SYSTEMS INC
Close on Oct 19, 2026
- Market cap
- $5.40B
- P/E (TTM)
- 37.2
- Dividend yield
- –
Earnings
Next report expected Oct 29, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 30, 2026 | During market hours | $418.80M | $0.65 | $1.19 |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 30, 2026 | During market hours | $381.90M | $0.68 | $0.94 |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 8, 2026 | During market hours | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Oct 30, 2025 | During market hours | $384.20M | $0.46 | $0.92 |
| Q2 FY2025 Ended Jun 30, 2025 | Jul 30, 2025 | During market hours | $382.50M | $0.54 | $1.01 |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 24, 2025 | During market hours | $355.40M | $0.49 | $0.86 |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 25, 2025 | During market hours | $355.20M | $0.46 | $0.93 |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | During market hours | $339.80M | $0.48 | $0.86 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | During market hours | $338.00M | $0.61 | $0.92 |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 30, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 8, 2024 | Before market open | – | – | – |
Company guidance
Outlook given with results on Apr 30, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Non-GAAP Earnings Per Sharenon-GAAP | Year Ending December 31, 2026 | $4.01 to $4.15 | New |
| Total Revenue | Year Ending December 31, 2026 | $1.61B to $1.63B | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Merit Medical Systems filed with the SEC
Merit Medical Announces Global Operations Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS SECOND QUARTER 2026 RESULTS AND UPDATES FULL-YEAR 2026 GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
SUMMARY OF MERIT MEDICAL SYSTEMS, INC. 2026 EQUITY INCENTIVE PLAN
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Summary of Merit Medical Systems, Inc. 2026 Employee Stock Purchase Plan
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Shareholders Elect Scott R. Ward to Board of Directors
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.3 to Form 8-K
MERIT MEDICAL REPORTS FIRST QUARTER 2026 RESULTS AND UPDATES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Acquires View Point Medical, Inc., expanding the Merit Therapeutic Oncology Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 RESULTS AND ISSUES FISCAL YEAR 2026 GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements include, among others: statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis .
Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements include, among others: statements preceded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Signs Asset Purchase Agreement with PENTAX Medical to acquire C2 CryoBalloon Technology
Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements include, among others: statements proceeded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Names Martha Aronson as New President and Chief Executive Officer
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Merit Medical Acquires Biolife Delaware, L.L.C.
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements include, among others: statements proceeded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MERIT MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS AND ISSUES FISCAL YEAR 2025 GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
statements include, among others: statements proceeded or followed by, or that include the words, “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “intends,” “seeks,” “believes,” “estimates,” “projects,” “forecasts,” “potential,” “target,”
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Systems Wrapsody Investor Conference Call Remarks
Regulation FD disclosure · EX-99.1 to Form 8-K
MERIT MEDICAL ANNOUNCES PRELIMINARY UNAUDITED REVENUE FOR THE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical Announces Resignation of President, Joseph Wright
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical
Other events · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS THIRD QUARTER 2024 RESULTS AND RAISES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
and non-GAAP), net income (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), free cash flow and other financial measures, future growth and profit expectations or forecasted economic conditions, or the
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical®
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients
Material agreement · Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
MERIT MEDICAL REPORTS SECOND QUARTER 2024 RESULTS AND RAISES FULL-YEAR GUIDANCE
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
margin (GAAP and non-GAAP), net income (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), free cash flow and other financial measures, future growth and profit expectations or forecasted
Results of operations · Regulation FD disclosure · EX-99.3 to Form 8-K
Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc. ®
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Merit Medical Shareholders Elect Silvia M. Perez as New Director
Material agreement · Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Merit Medical Executive Leadership Team Update
Executive or director change · Other events · EX-99.1 to Form 8-K
MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2024
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
income (GAAP and non-GAAP), operating income and margin (GAAP and non-GAAP), gross profit and margin (GAAP and non-GAAP), earnings per share (GAAP and non-GAAP), free cash flow, and
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K